Case Narrative
Multiple Myeloma Adult Patient
Standard-risk myeloma patient in sCR following autologous stem cell transplant
Clinical MRD Patient Cases
This site is designed to enable clinicians to access and share de-identified summaries of real patient cases for which measurable residual disease (MRD) testing has been utilized in clinical practice. These cases have been collected from current clonoSEQ users to illustrate the ways in which clonoSEQ MRD testing is being incorporated in the day-to-day management of myeloma and acute lymphoblastic leukemia (ALL) patients.
Scroll down to review the case library, or use the filters below to search for a case with specific characteristics. To submit a case for one of your own patients, click here.
Patient Case Results:
Case Narrative
Multiple Myeloma Adult Patient
Myeloma patient with high-risk cytogenetics (17p deletion) and renal comorbidities
Case Narrative
Acute Lymphoblastic Leukemia Young Adult Patient *
Post-transplant clonoSEQ Tracking (MRD) Testing revealed measurable residual disease (MRD); flow cytometry results did not detect measurable residual disease.
Case Narrative
Acute Lymphoblastic Leukemia Pediatric Patient
clonoSEQ Tracking (MRD) testing revealed early signs of relapse post-transplant.
Case Narrative
Acute Lymphoblastic Leukemia Adult Patient *
Adult acute lymphoblastic leukemia (ALL) patient; Philadelphia chromosome (Ph)-negative with standard risk features.
Case Narrative
Acute Lymphoblastic Leukemia Young Adult Patient *
clonoSEQ Tracking (MRD) Testing in the peripheral blood revealed early signs of relapse post-transplant.
Case Narrative
Acute Lymphoblastic Leukemia Adult Patient
Sensitivity of clonoSEQ MRD Assay allowed for early detection of relapse in post-transplant adult ALL patient.
* This patient case includes examples of clonoSEQ MRD testing in blood. Blood-based MRD testing for patients with acute lymphoblastic leukemia is available as a CLIA-regulated laboratory developed test (LDT) service provided by Adaptive Biotechnologies. This use of clonoSEQ has not been approved or cleared by the FDA. clonoSEQ is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies for use in B-cell acute lymphoblastic leukemia and multiple myeloma patients to detect and monitor measurable residual disease (MRD) in bone marrow samples. clonoSEQ is also available for use in other lymphoid cancers as a CLIA-regulated laboratory developed test (LDT) service provided by Adaptive Biotechnologies. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please review the Technical Summary, clonoseq.com/technical-summary.
Submit a Patient Case
Do you have an MRD case from your own practice that you would
like to share?
Fill out an online case form and submit for
review by Adaptive Medical Affairs, or download the form and
email a completed version to casestudies@adaptivebiotech.com.
